Townshend-Bulson L, Roik E, Barbour Y, et al. - The safety, tolerability, and efficacy outcomes of sofosbuvir- based regimens for treatment of HCV were evaluated in Alaska Native/American Indian (AN/AI) people in a real life setting.

• Within the Alaska Tribal Health System, a total of 501 AN/AI patients with a mean age of 54.3 (range 21.3–78.3) with confirmed positive anti-HCV and HCV RNA were included in the study.

• Overall, 95.2% of patients, who received one of the three DAA regimens, achieved SVR.

• Overall SVR was 92.8% for those with cirrhosis, and 91.1% for those with genotype 3.

• Sofosbuvir-based treatment is identified as safe, effective, and well tolerated in AN/AI patients in this real-world setting.

• Regardless of HCV genotype or cirrhosis status, high sustained virologic response was observed.